Literature DB >> 27728938

[Formative Evaluation of the "MBO® Kompakt-Neurowoche" - An Intensified Work-Related Rehabilitation Program for Neurological Patients].

M Schuler1, M Lukasczik1, H Laterveer2, F Weilbach2, M Presl, M Presl, J Knörzer2, S Neuderth1.   

Abstract

Objectives: The MBO® Kompakt-Neurowoche is offered as a work-related medical rehabilitation measure (based on allocation by a physician) following a regular neurological rehabilitation program with a duration of 7 days. Program access, process, and outcomes were examined in terms of a formative evaluation. Method: Pre-post-questionnaire data from 5 data points were used: start of regular rehabilitation (T0); start of work-related rehabilitation (T1); end of work-related rehabilitation (T2); 6-months follow-up (T3); 12-months follow-up (T4).
Results: N=252 patients (75% male, 48±10 years) were included. Participants report a higher work-related treatment motivation and a more positive subjective return-to-work prognosis as compared to nonparticipants (N=215). At T4, 76% are (very) satisfied with the program. Patients rate therapy elements focusing on the assessment and improvement of work-related capacity and memory as especially useful. Assistance in developing job-related alternatives should be optimized. Conclusions: Patients participating in the work-related program report both vocational problems and a high motivation to deal with these problems during rehabilitation. The program is rated as useful with regard to return to work and the management of workplace issues. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2016        PMID: 27728938     DOI: 10.1055/s-0042-116582

Source DB:  PubMed          Journal:  Rehabilitation (Stuttg)        ISSN: 0034-3536            Impact factor:   1.113


  1 in total

1.  [Clinical anamnestic characteristics in neurological work-related medical rehabilitation : Necessity for a qualitative identification of severe restrictions of work ability].

Authors:  A Heßling; I Brandes; M-L Dierks; T Leniger
Journal:  Nervenarzt       Date:  2018-02       Impact factor: 1.214

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.